Financial Survey: Curaleaf (CURLF) versus Its Rivals

Curaleaf (OTCMKTS:CURLFGet Rating) is one of 57 public companies in the “Medicinals & botanicals” industry, but how does it compare to its peers? We will compare Curaleaf to related businesses based on the strength of its profitability, institutional ownership, dividends, risk, valuation, analyst recommendations and earnings.

Profitability

This table compares Curaleaf and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Curaleaf -9.72% -7.08% -3.70%
Curaleaf Competitors 464.52% -8.40% 112.33%

Analyst Ratings

This is a summary of recent ratings for Curaleaf and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curaleaf 0 1 7 0 2.88
Curaleaf Competitors 188 527 723 41 2.42

Curaleaf presently has a consensus price target of $12.25, indicating a potential upside of 85.05%. As a group, “Medicinals & botanicals” companies have a potential upside of 148.50%. Given Curaleaf’s peers higher probable upside, analysts plainly believe Curaleaf has less favorable growth aspects than its peers.

Institutional & Insider Ownership

15.4% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 29.5% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Curaleaf and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Curaleaf $1.21 billion -$101.73 million -36.78
Curaleaf Competitors $265.37 million -$99.14 million -10.49

Curaleaf has higher revenue, but lower earnings than its peers. Curaleaf is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Curaleaf peers beat Curaleaf on 8 of the 12 factors compared.

About Curaleaf

(Get Rating)

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels. The Non-Cannabis Operations segment provides professional services, including cultivation, processing, and retail know-how and back-office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements. It offers flowers, pre-rolls, flower pods, and dry-herb vaporizer cartridges; concentrates for vaporizing, such as pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, including distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. The company also provides hemp-based CBD products. As of June 16, 2022, it operated 134 dispensaries and 26 cultivation sites in 22 states of the United States. The company was founded in 2010 and is headquartered in Wakefield, Massachusetts.

Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.